Drug Development Updates

Stay informed with timely notifications on clinical trials and research advancements.

Bucillamine

Generic Name: Bucillamine

Drug Type: Small Molecule

Chemical Formula: C_₇H_₁₃NO_₃S_₂

CAS Number: 65002-17-7

Unique Ingredient Identifier: R80LRA5WTF

Overview

Bucillamine has been used in trials studying the treatment and prevention of Gout and Rheumatoid Arthritis.

Background

Bucillamine has been used in trials studying the treatment and prevention of Gout and Rheumatoid Arthritis.

Indication

No indication information available.

Associated Conditions

No associated conditions information available.

Clinical Trials

Bucillamine in Treatment of Patients With COVID-19

Phase 3

Terminated

Posted: 2020/08/07

Sponsor:Revive Therapeutics,...

ID:NCT04504734

Bucillamine Phase 2 Trial in Patients With Cystinuria

Phase 2

Posted: 2016/10/24

Sponsor:Revive Therapeutics,...

ID:NCT02942420

A Study Assessing the Safety and Efficacy of Sarilumab Added to Non-MTX DMARDs or as Monotherapy in Japanese Patients With Active Rheumatoid Arthritis (SARIL-RA-HARUKA)

Phase 3

Completed

Posted: 2015/02/26

Sponsor:Sanofi

ID:NCT02373202

Bucillamine for the Treatment of Acute Gout Flare in Subjects With Moderate to Severe Gout

Phase 2

Completed

Posted: 2015/01/05

Sponsor:Revive Therapeutics,...

ID:NCT02330796

Bucillamine Study of Holding Remission After Infliximab Dose-off

Phase 4

Posted: 2008/07/16

Sponsor:Saitama Medical Univ...

ID:NCT00716248

FDA Approved Products

No FDA products found for this drug

Singapore Approved Products

No Singapore products found for this drug

Related News

No news found

Drug Development Updates

Stay informed with timely notifications on clinical trials and research advancements.

Home Terms & Conditions Privacy Policy